APP and Alzheimer disease: Erinacines, the bioactive compounds of Hericium erinaceus mushroom, have been reported to have a neuroprotective effect in APP/PS1 mice [27, 28]; however, their potential to modulate microglial morphology, elucidate underlying mechanisms of action, and address metabolic dysfunction in AD has not been thoroughly investigated.